Clinical Trials Using Sorafenib Tosylate

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Sorafenib Tosylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 35
1 2 Next >

  • Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer

    This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy, uses focused, high-dose radiation to help shrink tumors. It is not yet known whether giving sorafenib tosylate together with stereotactic body radiation therapy is more effective than sorafenib tosylate alone in treating liver cancer.
    Location: 27 locations

  • Sorafenib Tosylate with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer

    This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with thyroid cancer that has spread to other places in the body or cannot be removed by surgery and has not responded to treatment with radioactive iodine. Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of everolimus to sorafenib tosylate may cause more shrinkage of thyroid cancer and may prevent it from growing but it could also cause more side effects than sorafenib tosylate alone. It is not yet known whether this treatment with sorafenib tosylate and everolimus is better, the same, or worse than sorafenib tosylate alone.
    Location: 19 locations

  • Navitoclax and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Solid Tumors

    This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 10 locations

  • Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

    This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
    Location: 10 locations

  • Azacitidine or Decitabine in Epigenetic Priming in Patients with Newly Diagnosed Acute Myeloid Leukemia

    This randomized phase II trial studies how well azacitidine or decitabine work in epigenetic priming in patients with newly diagnosed acute myeloid leukemia. Azacitidine and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 6 locations

  • Sorafenib Tosylate and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases from Breast Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with whole brain radiation therapy in treating patients with breast cancer that has spread to the brain. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving sorafenib tosylate and whole-brain radiation therapy together may kill more tumor cells.
    Location: 6 locations

  • Enzalutamide with or without Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer

    This phase I / II trial studies the side effects and the best dose of enzalutamide when given with or without sorafenib tosylate and to see how well it works in treating patients with liver cancer (hepatocellular carcinoma) that has spread to other places in the body and usually cannot be cured or controlled with treatment. Enzalutamide binds to proteins called androgen receptors, which are found in hepatocellular carcinoma and this may keep tumor cells from growing. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may also prevent the growth of new blood vessels that tumors need to grow. It is not yet known whether enzalutamide is more effective with or without sorafenib tosylate in treating patients with liver cancer.
    Location: 7 locations

  • Sorafenib and Cyclophosphamide / Topotecan in Patients With Relapsed and Refractory Neuroblastoma

    This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclophosphamide and topotecan. This is the first study to test giving these three drugs together and will help determine the highest dose of sorafenib that can safely be given together with cyclophosphamide and topotecan to patients with resistant / relapsed neuroblastoma.
    Location: 5 locations

  • An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

    The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus (HCV)-infected HCC subjects, and hepatitis B virus (HBV)-infected subjects). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses for each of the 3 cohorts. A third cohort has been added in this study to compare the efficacy of nivolumab and sorafenib in the treatment of Advanced HCC. A fourth cohort will generate data on the safety and efficacy of the combination nivolumab plus ipilimumab in the treatment of Advanced HCC. In the fifth cohort, additional clinical data will be generated for Child-Pugh B subjects. A Cabozantinib Combination Cohort has been added to evaluate the safety and tolerability of nivolumab in combination with cabozantinib and nivolumab with ipilimumab in combination with cabozantinib.
    Location: 4 locations

  • Trial of TRC105 and Sorafenib in Patients With HCC

    The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma. Up to 18 patients will be treated. The purpose of the phase 2 portion is to estimate the ORR of patients with hepatocellular carcinoma by RECIST 1.1. Up to 21 patients will be treated in phase 2.
    Location: 5 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
    Location: 3 locations

  • Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection

    This phase IV trial studies how well the Food and Drug Administration (FDA) approved drug, sorafenib tosylate, works in treating patients with advanced liver cancer and hepatitis C infection. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
    Location: 5 locations

  • Sapanisertib or Sorafenib Tosylate in Treating Patients with Advanced or Metastatic Liver Cancer

    This randomized phase I / II trial studies the side effects and best dose of sapanisertib and how well sapanisertib or sorafenib tosylate works in treating patients with that has spread to other places in the body. Sapanisertib and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Risk Adapted Focal Proton Beam Radiation and / or Surgery in Participants with Low, Intermediate, and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    This phase II trial studies how well chemotherapy, surgery, and radiation therapy work in treating patients with newly diagnosed rhabdomyosarcoma that has spread to other parts of the body. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.
    Location: 3 locations

  • Sorafenib Tosylate and Pembrolizumab in Treating Patients with Advanced or Metastatic Liver Cancer

    This phase Ib / II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and pembrolizumab may work better in treating patients with liver cancer.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Sorafenib Tosylate and Hydroxychloroquine Sulfate in Treating Patients with Advanced or Metastatic Liver Cancer

    This phase II trial studies how well sorafenib tosylate and hydroxychloroquine sulfate work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hydroxychloroquine sulfate may increase the effectiveness of sorafenib tosylate. Giving sorafenib tosylate and hydroxychloroquine may work better in treating patients with liver cancer.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Sorafenib Tosylate, Bavituximab, and Stereotactic Body Radiation Therapy as First Line Therapy in Treating Patients with Advanced Liver Cancer That Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with sorafenib tosylate and bavituximab as first line therapy in treating patients with liver cancer that has spread to other places in the body and cannot be removed by surgery. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bavituximab, interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving sorafenib tosylate, bavituximab, and stereotactic body radiation therapy as first line therapy may work better in treating patients with liver cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Personalized Kinase Inhibitor Therapy Combined with Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia

    This phase IB trial studies the feasibility of using a functional laboratory based study to determine how well the test can be used to select personalized kinase inhibitor therapy in combination with standard chemotherapy in treating patients with newly diagnosed acute myeloid leukemia (AML). It also evaluates safety and potential efficacy. Kinase inhibitor is a type of substance that blocks an enzyme called a kinase. Human cells have many different kinase enzymes, and they help control important cell functions. Certain kinases are more active in some types of cancer cells and blocking them may help keep the cancer cells from growing. Testing samples of blood from patients with AML in the laboratory with kinase inhibitors may help determine which kinase inhibitor has more activity against cancer cells and which one should be combined with standard of care chemotherapy. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving a personalized kinase inhibitor therapy combined with standard chemotherapy may be a better treatment for AML.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Sorafenib Tosylate and Irinotecan Hydrochloride in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors

    This phase II trial studies how well sorafenib tosylate and irinotecan hydrochloride work in treating pediatric patients with solid tumors that have returned after a period of improvement or have not responded to previous treatment. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sorafenib tosylate and irinotecan hydrochloride may work better in treating pediatric patients with recurrent or refractory solid tumors.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Filgrastim, Cladribine, Cytarabine, and Mitoxantrone with Sorafenib Tosylate in Treating Patients with Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    This phase I / II trial studies the side effects and best dose of filgrastim (granulocyte colony-stimulating factor [G-CSF]), cladribine, cytarabine, and mitoxantrone hydrochloride, when given together with sorafenib tosylate and to see how well they work in treating patients with newly-diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (likely to be more aggressive). Drugs used in chemotherapy, such as filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride together with sorafenib tosylate may kill more cancer cells.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Second Line Treatment with Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

    This phase II trial studies how well pemetrexed disodium and sorafenib tosylate work in treating patients with triple negative breast cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Selinexor and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

    This phase I / II trial studies the side effects and best dose of selinexor when given together with sorafenib tosylate and to see how well they work in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Selinexor and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Sorafenib Tosylate, Vorinostat, Gemcitabine Hydrochloride, and Radiation Therapy in Treating Patients with Pancreatic Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate and vorinostat when given together with gemcitabine hydrochloride and radiation therapy in treating patients with pancreatic cancer. Sorafenib tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving sorafenib tosylate, vorinostat, gemcitabine hydrochloride, and radiation therapy may be a better treatment for pancreatic cancer.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Trametinib and Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer

    This phase I trial studies the side effects and best doses of trametinib and sorafenib tosylate in treating patients with liver cancer that has spread to other places in the body. Trametinib and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Sorafenib Tosylate and Yttrium Y 90 Bead Therapy in Treating Patients with Advanced Liver Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with yttrium Y 90 bead therapy in treating patients with liver cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioembolization is a technique that involves the use of small radioactive glass beads called microspheres. Microsphere radiation therapy is delivered to the tumor through a catheter, which is a long tube inserted by a radiologist under x-ray guidance through the leg artery and directly up into the liver arteries. Before the radioembolization procedure, the radiologist will have injected a special dye so that the different arteries can be seen and the correct ones can be chosen (this is called an angiogram). The physician then inserts the microspheres directly through the catheter into the tumor’s blood supply. Once infused, the beads travel to the tumor, where they give off small amounts of radiation to the tumor site for several days. Giving sorafenib tosylate together with yttrium Y 90 bead therapy may kill more tumor cells.
    Location: University of Hawaii Cancer Center, Honolulu, Hawaii


1 2 Next >